HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Cullinan Therapeutics (NASDAQ:CGEM) and maintained a price target of $28.
September 16, 2024 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Cullinan Therapeutics and maintained a price target of $28, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $28 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Cullinan Therapeutics' future performance. This could lead to increased investor interest and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100